Study of G1147211 in Cancer Treatment
Author Information
Author(s): L Paz-Ares, R Kunkal, D DeMaria, J Cassidy, M Alden, P Beranek, S Kaye, D Littlefield, D Reilly, S Depee, P Wissel, C Twelves, P O'Dwyer
Primary Institution: University of Glasgow
Hypothesis
The study aims to determine the maximum tolerated dose of G1147211 as a 72-hour infusion and to describe its pharmacokinetics and pharmacodynamics.
Conclusion
G1147211 is well tolerated as a 72-hour infusion with manageable side effects and shows promising anti-tumor activity.
Supporting Evidence
- Three partial responses lasting 8-34+ weeks were noted in patients with ovarian, colon, and breast carcinomas.
- Neutropenia was dose limiting at 2.0 mg m-2 day-1 in minimally pretreated patients.
- Mean steady-state concentrations of G1147211 increased with dose over a range of 0.25-1.24 ng ml-1.
Takeaway
Doctors tested a new cancer drug called G1147211 to see how much they can give safely, and it seems to help some patients with cancer.
Methodology
A single-arm, rising-dose study where patients received 72-hour infusions of G1147211 at varying doses.
Potential Biases
Potential bias due to the single-arm design and lack of control group.
Limitations
The study had a small sample size and was limited to patients with advanced cancer.
Participant Demographics
Patients had advanced cancer, with a median age of 60 years, and included equal numbers of men and women.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website